Halozyme Therapeutics, Inc. (HALO) Posts Surprise Q2 Profit
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
Revenue Growth %: +36.2%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +36.2%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of $0.03, $0.16 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $4.95 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme prices $1.3B convertible notes offering due 2033
- High Tide Inc. (HITI) Tops Q2 EPS by 11c
- Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
